Skip to main navigation
Skip to content
Skip to content
PDL Logo Blue Green
  • About PDL
  • Leadership
  • Investor Relations
  • About PDL
    • Management
  • Portfolio of Assets
  • Investor Relations
  • News
  • Contact

Press Releases

PDL  > Investor Relations > Press Releases

Press Releases

  • Summary TogglePDL BioPharma to Announce First Quarter 2019 Financial Results on May 9, 2019
    INCLINE VILLAGE, Nev. , May 2, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its first quarter 2019 financial results for the period ended March 31, 2019 , on Thursday, May 9, 2019 , after market close.
    May 2, 2019
  • Summary TogglePDL BioPharma to Hold Annual Meeting of Stockholders on June 20, 2019
    INCLINE VILLAGE, Nev. , April 16, 2019 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Thursday, June 20, 2019 , at 3:00 p.m. Pacific Time for all stockholders of record on April 26, 2019 .
    Apr 16, 2019
  • Summary TogglePDL BioPharma Announces Equity Investment in Evofem Biosciences
    Transaction supports strategy of investing in near-commercial stage products with potential to create significant shareholder value Provides Evofem capital to prepare for the successful launch of Amphora® (L-lactic acid, citric acid, and potassium bitartrate), a novel, investigational non-hormonal,
    Apr 11, 2019
  • Summary TogglePDL BioPharma to Participate at H.C. Wainwright & Co. Global Life Sciences Conference
    INCLINE VILLAGE, Nev. , March 26, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, and Peter Garcia , PDL's chief financial officer, will present at the H.C. Wainwright & Co.
    Mar 26, 2019
  • Summary TogglePDL BioPharma Reports 2018 Fourth Quarter and Full Year Financial Results
    INCLINE VILLAGE, Nev. , March 14, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and 12 months ended December 31, 2018 : Financial Highlights Total revenues of $45.1 million for the 2018 fourth quarter and $198.1 million for
    Mar 14, 2019
  • Summary TogglePDL BioPharma to Participate at 31st Annual Roth Conference
    INCLINE VILLAGE, Nev. , March 12, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Peter Garcia , PDL's vice president and chief financial officer, will participate in a series of investor meetings at the 31 st Annual Roth Conference being held March
    Mar 12, 2019
  • Summary TogglePDL BioPharma to Announce 2018 Fourth Quarter and Full Year Financial Results on March 14, 2019
    INCLINE VILLAGE, Nev. , March 7, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its 2018 fourth quarter and full year financial results for the period ended December 31, 2018 , on Thursday, March 14, 2019 , after market
    Mar 7, 2019
  • Summary TogglePDL BioPharma to Participate at Cowen 39th Annual Health Care Conference
    INCLINE VILLAGE, Nev. , March 5, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that Dominique Monnet , PDL's president and chief executive officer, and Peter Garcia , PDL's chief financial officer, will present at the Cowen 39 th Annual Health Care
    Mar 5, 2019
  • Summary TogglePDL BioPharma Announces Launch of an Authorized Generic of Tekturna® (aliskiren) in Partnership with Prasco Laboratories
    INCLINE VILLAGE, Nev. , March 4, 2019 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL", NASDAQ: PDLI) announces the U.S. commercial launch of an authorized generic of Tekturna ® , aliskiren hemifumarate 150 mg and 300 mg tablets.  The authorized generic has the same drug formulation as Tekturna.
    Mar 4, 2019
  • Summary TogglePDL BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference
    INCLINE VILLAGE, Nev. , Nov. 19, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that management will present at the Piper Jaffray Healthcare Conference in New York City.  The session will be webcast live and will occur on Tuesday, November 27, 2018 , at
    Nov 19, 2018
  • Summary TogglePDL BioPharma Reports Third Quarter 2018 Financial Results
    Announces CEO succession plan INCLINE VILLAGE, Nev. , Nov. 6, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) reports financial results for the three and nine months ended September 30, 2018 including: Third Quarter Financial Highlights Total revenues of $67.9
    Nov 6, 2018
  • Summary TogglePDL BioPharma to Announce Third Quarter Financial Results on November 6, 2018
    INCLINE VILLAGE, Nev. , Oct. 31, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that it will release its third quarter financial results for the period ended September 30, 2018 , on Tuesday, November 6, 2018 , after market close.  PDL's management
    Oct 31, 2018
  • Summary TogglePDL BioPharma Names Edward Imbrogno Vice President of Finance
    INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position.  Mr. Imbrogno brings to PDL more than 30 years of public accounting and financial reporting experience and will
    Oct 8, 2018
  • Summary TogglePDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
    INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference in New York City. The session will be webcast
    Sep 26, 2018
  • Summary TogglePDL BioPharma Announces New $100 Million Stock Repurchase Program
    INCLINE VILLAGE, Nev. , Sept. 24, 2018 /PRNewswire/ --  PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock.  Purchases may be made in open-market transactions, in block
    Sep 24, 2018

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page Next
  • Last page Last

    Investor Relations

    • Frequently Asked Questions (FAQ)
    • Investor Updates
    • Press Releases
    • 2020 Proxy Statement
    • Tax Information
      • Common Stock Tax Information
      • Convertible Note Tax Information
    • SEC Filings
    • Contact Information

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • RSS
    • Print
    • Share
    • Search
    • Facebook
    • Google
    • LinkedIn
    • Twitter
    • RSS

PDL Logo White Fill

  • Terms of Use
  • Sitemap
© Copyright 2021 PDL BioPHARMA. All Rights Reserved.